WCA
AMPH icon

Westover Capital Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

Westover Capital Advisors’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,483
Closed -$648K – 186
2023
Q4 		$648K Buy
+10,483
New +$551K 0.21% 91

Other funds holding AMPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Westover Capital Advisors's AMPH Position: Q1 2024 in Review

Westover Capital Advisors sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2024, closing a stake of 10,483 shares — an estimated $648K sold.

Westover Capital Advisors first reported a position in AMPH in Q4 2023 and held it in 1 quarter. The position peaked at $648K in Q4 2023. 271 funds tracked by Wall St. Rank hold AMPH as of Q1 2024.

  • Westover Capital Advisors reported no remaining Amphastar Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Westover Capital Advisors sold 10,483 Amphastar Pharmaceuticals shares in Q1 2024, an estimated $648K.
  • Westover Capital Advisors first reported a position in Amphastar Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Westover Capital Advisors's Amphastar Pharmaceuticals position peaked at $648K in Q4 2023.
  • 271 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2024.

Based on Westover Capital Advisors's 13F filing for Q1 2024, filed 3 May 2024.